ECM
Endurant Capital Management Portfolio holdings
AUM
$17.4M
1-Year Return
4.95%
This Quarter Return
-18.92%
1 Year Return
+4.95%
3 Year Return
+16.8%
5 Year Return
+58.39%
10 Year Return
–
AUM
$189M
AUM Growth
-$35.6M
(-16%)
Cap. Flow
-$10M
Cap. Flow
% of AUM
-5.3%
Top 10 Holdings %
Top 10 Hldgs %
53.49%
Holding
84
New
11
Increased
22
Reduced
15
Closed
36
Top Buys
| 1 |
Zimmer Biomet
ZBH
|
$8.75M |
| 2 |
IIN
IntriCon Corporation
IIN
|
$5.61M |
| 3 |
AGN
Allergan plc
AGN
|
$5.42M |
| 4 |
Encompass Health
EHC
|
$5.26M |
| 5 |
MDRX
Veradigm Inc. Common Stock
MDRX
|
$4.96M |
Top Sells
| 1 |
TVTY
Tivity Health, Inc. Common Stock
TVTY
|
$9.99M |
| 2 |
SHPG
Shire pic
SHPG
|
$7.67M |
| 3 |
Abbott
ABT
|
$5.78M |
| 4 |
Merck
MRK
|
$5.68M |
| 5 |
Baxter International
BAX
|
$5.26M |
Sector Composition
| 1 | Healthcare | 91.46% |
| 2 | Industrials | 3.75% |
| 3 | Technology | 3.46% |
| 4 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Viatris
VTRS
$12.2B
| $2.11M | 1.12% |
77,135
-30,643
| -28% | -$839K |
|
27
Standard BioTools
LAB
$497M
| $2.04M | 1.08% |
236,648
-325,936
| -58% | -$2.81M |
|
|
RVLP
28
DELISTED
RVL Pharmaceuticals plc Ordinary Shares
RVLP
| $1.8M | 0.95% |
+232,048
| New | +$1.8M |
|
29
PetMed Express
PETS
$63M
| $1.56M | 0.82% |
+67,010
| New | +$1.56M |
|
30
Accuray
ARAY
$170M
| $1.55M | 0.82% |
+455,018
| New | +$1.55M |
|
|
ARRY
31
DELISTED
Array Biopharma Inc
ARRY
| $1.46M | 0.77% |
102,345
-10,355
| -9% | -$148K |
|
32
iRhythm Technologies
IRTC
$5.82B
| $1.25M | 0.66% |
+18,018
| New | +$1.25M |
|
33
Stryker
SYK
$150B
| $1.15M | 0.61% |
7,319
-19,502
| -73% | -$3.06M |
|
34
Teva Pharmaceuticals
TEVA
$21.7B
| $1.14M | 0.6% |
+73,884
| New | +$1.14M |
|
35
Boston Scientific
BSX
$159B
| $1.08M | 0.57% |
30,560
-39,847
| -57% | -$1.41M |
|
36
Ocular Therapeutix
OCUL
$2.37B
| $926K | 0.49% |
232,727
-69,426
| -23% | -$276K |
|
37
Johnson & Johnson
JNJ
$430B
| $850K | 0.45% |
6,588
+4,119
| +167% | +$531K |
|
38
Liquidia Corp
LQDA
$2.48B
| $848K | 0.45% |
39,139
+15,054
| +63% | +$326K |
|
39
Axogen
AXGN
$735M
| $816K | 0.43% |
39,961
+10,887
| +37% | +$222K |
|
40
AnaptysBio
ANAB
$613M
| $812K | 0.43% |
+12,734
| New | +$812K |
|
41
Cencora
COR
$56.7B
| $620K | 0.33% |
+8,340
| New | +$620K |
|
42
Axsome Therapeutics
AXSM
$6.25B
| $590K | 0.31% |
209,195
+114,010
| +120% | +$322K |
|
43
Amicus Therapeutics
FOLD
$2.46B
| $558K | 0.29% |
58,240
-12,528
| -18% | -$120K |
|
44
Aldeyra Therapeutics
ALDX
$334M
| $553K | 0.29% |
66,639
-3,361
| -5% | -$27.9K |
|
45
McKesson
MCK
$85.5B
| $549K | 0.29% |
4,966
+2,144
| +76% | +$237K |
|
46
Viking Therapeutics
VKTX
$3.03B
| $409K | 0.22% |
53,466
-18,511
| -26% | -$142K |
|
47
Krystal Biotech
KRYS
$4.35B
| $260K | 0.14% |
+12,500
| New | +$260K |
|
48
Agilent Technologies
A
$36.5B
| – | – |
-17,286
| Closed | -$1.22M |
|
|
49
Abbott
ABT
$231B
| – | – |
-78,718
| Closed | -$5.78M |
|
50
Acadia Pharmaceuticals
ACAD
$4.26B
| – | – |
-32,371
| Closed | -$672K |
|